FinTechFunding

Triad Life Sciences: Closes A$25M Funding

Triad Life Sciences Closes A$25M Funding

  • Triad Life Sciences, a Memphis, Tenn.-based biotech company, raised AUS$25m funding round
  • The convertible note placement was led by Cannacord Genuity
  • The company intends to use the funds for its US sales force expansion plans, R&D activities, and general working capital needs
  • Triad now plans to move forward with a listing on the Australian Securities Exchange (ASX) in the coming months
  • Led by CEO Russ Olsen, TriadLife Sciences is a biotech company focused on developing and commercializing biomaterials for treating complex surgical and chronic wounds
  • Triad recently received FDA clearance to market InnovaMatrix™, a next generation extracellular matrix (ECM) wound care device
Previous article
Lextegrity: Raises Additional $5M in Funding
Next article
Hive: Raises $10M in Funding
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Piraeus Strengthens AI Hub with Accenture and Anthropic Partnership

The collaboration aims to enhance AI capabilities in banking services.Highlights: Piraeus Bank collaborates with Accenture and Anthropic.The partnership...
FinTech

Lloyds Strengthens Leadership by Appointing Sameer Gupta as Chief Data and AI Officer

Gupta's expertise in data strategy aims to enhance Lloyds' digital transformation.Highlights: Lloyds Banking Group appoints Sameer Gupta as...
FinTech

Lydian Launches Visa Crypto Card, Expanding Digital Payment Options

The new Visa card aims to simplify cryptocurrency transactions for users.Highlights: Lydian's new Visa crypto card is now...
FinTech

Kraken Parent Acquires Bitnomial for $550M, Strengthening Crypto Offerings

This acquisition marks a significant expansion into derivatives trading.Highlights: Kraken's parent company announces $550M acquisition of Bitnomial.Bitnomial is...